Pingkian, Ruro Alistair .

HRN: 22-57-91  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/06/2023
OXACILLIN 500MG (VIAL)
02/06/2023
02/12/2023
IVT
170mg
Q6
Pcap D, Submandibular Mass
Waiting Final Action 

Indication:  EmpiricEmpirical Escalation    Type of Infection:  PneumoniaSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: